Elizabeth Mary Ruiz

Ms. Elizabeth Mary Ruiz

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 November 2025 in Cancers
Verified
Journal Article
Open access
PDF file
Govindarajan NarayananGovindarajan Narayanan
Govindarajan Narayanan
ERElizabeth Mary Ruiz
Elizabeth Mary Ruiz
MDMadelon Dijkstra
Madelon Dijkstra
NGNicole T. Gentile
Nicole T. Gentile
DDDanielle Donahue
Danielle Donahue
BBBente van den Bemd
Bente van den Bemd
Objectives: This single-center retrospective study evaluates the clinical efficacy and safety of percutaneous ablation using microwave ablation (MWA) and irreversible electroporation (IRE) in patients with breast cancer liver metastases (BCLM). Methods: Between August 2018 and December 2023, 32 patients underwent 40 image-guided ablations for 57 BCLM. Mean age was 61.3 years (range: 32–85), and mean tumor size was 2.9 cm (range: 0.9–7.0 cm). Fifty lesions were treated with MWA and seven with IRE. Clinical efficacy was assessed by m-RECIST response at first follow-up imaging (after ≥1 month) and by monitoring local tumor progression (LTP), local tumor progression-free survival (LTPFS), and overall survival (OS). Safety was evaluated by adverse events according to CTCAE. Kaplan–Meier statistics were used for LTPFS and OS. Results: Median follow-up was 32.4 months (95% CI 16.6–48.0). Complete response was observed in 34 tumors (59.6%), partial response in 14 (24.6%), and progressive disease in 9 (15.8%). LTP occurred in 37 tumors (64.9%), with a median time to progression of 11.1 months (95% CI 1.4–20.8). One- and two-year LTPFS rates were 43.6% and 34.1%. Sixteen patients died during follow-up, with median OS of 27.8 months (95% CI 19.0–36.6) and 1- and 2-year OS rates of 90.1% and 55.9%. No major complications occurred. Complications included eight Grade 1 and two Grade 2 complications. Conclusions: Percutaneous ablation demonstrates clinical efficacy and a favorable safety profile in selected BCLM patients, achieving OS comparable to the current literature. Further studies should clarify its additive role within multimodality treatment.

7 March 2026 in Journal of Vascular and Interventional Radiology
Verified
Journal Article
Open access
GNGovindarajan Narayanan
Govindarajan Narayanan
ERElizabeth Mary Ruiz
Elizabeth Mary Ruiz
MDMadelon Dijkstra
Madelon Dijkstra
BBBente van den Bemd
Bente van den Bemd
AMAshwin Mahendra
Ashwin Mahendra
SLSusan van der Lei
Susan van der Lei
To evaluate the safety and accuracy of robot-assisted microwave ablation (MWA) for primary and secondary liver tumors using the Epione (Quantum Surgical, Montpellier, France) robotic system. This single-center retrospective study included all computed tomography (CT)-guided robotic MWA procedures performed at the Miami Cancer Institute, Baptist Health South Florida from May 2023 to March 2025. Primary endpoints were safety, assessed by adverse events related to robotic guidance or ablation, and accuracy, defined by the need for minor (depth/lateral) or major (antenna removal and reinsertion) adjustments. Secondary endpoints included feasibility, technical success, local tumor progression (LTP), LTP-free survival (LTPFS), and local control (LC). A total of 153 robot-assisted antenna placements were performed to treat 152 tumors in 78 patients. Robotic placement was feasible in 98.7% (77/78) of patients. Technical success was achieved in 96.8% (152/157) of trajectories. Among all trajectories, 18.5% (29/157) required no adjustment, 62.4% (98/157) required minor depth adjustment, 17.8% (28/157) required minor lateral adjustment, and 3.2% (5/157) required major adjustment. Of major adjustments, 4 were corrected with robotic reinsertion, and 1 was corrected manually. Mean preadjustment lateral deviation was 5.6 mm (SD ±3.9). Adverse events occurred in 14.1% (11 Grade 1, 2 Grade 2, and 1 Grade 3) of procedures, none directly related to robotic guidance. Median follow-up was 6.9 months. The 6-month LTPFS per tumor for patients treated in the first versus second year was 87.1% versus 94.9%, respectively (hazard ratio, 0.385; 95% confidence interval, 0.083-1.771; P = .220). Robotic guidance for liver MWA demonstrated high feasibility, excellent technical success, and low placement error with no robot-related complications, supporting its safety and accuracy in clinical practice.

20 August 2026 in Journal of Clinical Interventional Radiology ISVIR
Verified
Journal Article
Open access
GNGovindarajan Narayanan
Govindarajan Narayanan
ERElizabeth Mary Ruiz
Elizabeth Mary Ruiz
NGNathan C. Gilmore
Nathan C. Gilmore
BBBente van den Bemd
Bente van den Bemd
GLGina P. Landinez
Gina P. Landinez
SLSusan van der Lei
Susan van der Lei
The aim of this study was to assess balloon dissection as an adjunctive technique during percutaneous thermal ablation of renal and hepatic tumors near critical structures. In this retrospective study, patients underwent CT-guided percutaneous ablation under general anesthesia for tumors located ≤1 cm from critical structures. A Yueh needle was used to access the space between the tumor and the critical structure, followed by Bentson wire insertion and vascular sheath placement to position a balloon, which was then inflated to create separation. The primary objectives were feasibility, safety, and technical success. Feasibility was defined as successful balloon placement; safety as procedure-related adverse events; and technical success as complete ablation with a >5 mm margin on immediate post-procedure imaging. Twelve patients underwent image-guided percutaneous ablation of kidney and liver lesions. Balloon placement between the target tumor and the adjacent bowel was successful in all cases. Six patients (50%) received cryoablation for renal cell carcinoma (RCC), and six (50%) underwent microwave ablation (MWA) for hepatocellular carcinoma (HCC, n = 2), colorectal liver metastases (CRLM, n = 2), and RCC liver metastases (n = 2). Mean tumor size was 3.7 cm (SD, 1.5) for renal tumors and 3.0 cm (SD, 1.3) for hepatic tumors. Technical success with sufficient tumor margins was achieved in all cases, and no thermal injury to adjacent structures was observed. One grade 1 and two grade 2 complications occurred, unrelated to balloon insertion. Balloon dissection is a technically feasible and safe technique to facilitate thermal ablation of renal and hepatic tumors located in proximity to critical structures.